Ultime notizie per Sage Therapeutics (NASDAQ:SAGE) Azioni

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Inc

SAGE GROUP ORD

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

On October&nbsp;31, 2024 (the "Separation Date"), Kimi Iguchi and Sage Therapeutics, Inc. (the "Company") entered into a separation agreement (the "Iguchi Separation Agreement") providing for the resignation of Ms.&nbsp;Iguchi from her positions as the Chief Financial Officer and Treasurer of the Company and from any and all other positions she holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries. As previously announced, Ms.&nbsp;Iguchi's departure from the Company was part of the October 2024 reorganization of the Company's business operations and reduction in the Company's workforce (the "Reorganization"). The Iguchi Separation Agreement also includes a release of claims by Ms.&nbsp;Iguchi and non-solicitation, non-disclosure and non-disparagement obligations following the Separation Date.

News

Management

SAGE

Sage Therapeutics Announces Resignation Of Kimi Iguchi From Her Position As CFO And Treasurer Of The Co And From Any And All Other Positions She Holds As An Officer Or Employee Of The Company Or An Officer, Employee Or Director Of Any Of Its Subsidiaries

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $17 to $14.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Yasmeen Rahimi reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Overweight and lowers the price target from $52 to $26.

Reiteration

Piper Sandler Reiterates Overweight on Sage Therapeutics, Lowers Price Target to $26

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANAB

APDN

CALC

CRMD

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OMCL

OPCH

THAR

12 Health Care Stocks Moving In Wednesday's Intraday Session

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Perform and lowers the price target from $9 to $8.

Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $8

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $13 to $8.

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $8

WIIM

Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Additionally, HC Wainwright & Co. cut its price target on the stock from $25 to $14.

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $25 to $14.

HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $14

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

Needham Reiterates Hold on Sage Therapeutics

Guidance

Sage Therapeutics Does Not Anticipate Receipt Of Any Milestone Payments From Collaborations In Remainder Of 2024; Anticipates ZULRESSO Use Will Continue To Decrease And Has Decided To No Longer Make ZULRESSO Commercially Available As Of December 31, 2024

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.52) by 0.66 percent. The company reported quarterly sales of $11.871 million which beat the analyst consensus estimate of $10.802 million by 9.89 percent. This is a 337.08 percent increase over sales of $2.716 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sage Therapeutics to report an earnings per share (EPS) of $-1.55.
Sage Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.04, leading to a 10.87% drop in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2024/1730131343_0.png" alt="eps graph" />
<h3>Performance of Sage Therapeutics Shares</h3>
Shares of Sage Therapeutics were trading at $8.01 as of October 25. Over the last 52-week period, shares are down 57.32%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SAGE/earnings">To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sage Therapeutics's Earnings: A Preview

On Thursday, Sage Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-" rel="noreferrer noopener">in postpartum depression</a>.
The reorganization is intended to enable Sage to strengthen its balance sheet, extend its cash runway, and position the company for long-term growth potential.
The reorganization is planned to be substantially completed by the end of the fourth quarter of 2024.
The company will lay off over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&amp;D workforce), including changes to the leadership team.
Sage expects a non-recurring charge of approximately $26 million to $28 million associated with the reorganization.
The company anticipates that implementing the restructuring will extend its cash runway. Sage will also implement early-stage pipeline prioritization.
The company will focus its pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington&#8217;s Disease, which is expected later this year.
In July, Sage and Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) announced to close the ongoing open-label safety study of SAGE-324 in essential tremor and do not plan to conduct further clinical development of SAGE-324 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" rel="noreferrer noopener">in essential tremor</a>.
The KINETIC 2 study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score.
In September, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">SAGE-324 program</a>.
Last week, Sage pulled a plug on the further clinical development of dalzanemdor in Alzheimer&#8217;s after the LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the study&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41228587/after-disappointing-parkinsons-data-sage-therapeutics-dalzanemdor-flunks-mid-stage-alzheimers-stu" rel="noreferrer noopener">primary outcome measure</a>.
Price Action: SAGE stock is down 4.81% at $6.92 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41381149/shiftpixys-big-ai-move-supercharges-workforce-management-with-150m-turboscale-deal" target="_blank" rel="noreferrer noopener">ShiftPixy&#8217;s Big AI Move: Supercharges Workforce Management With $150M TurboScale Deal</a>.</li>
</ul>

Biotech

Health Care

General

BIIB

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

The reorganization is planned to be substantially completed by the end of the 4th quarter of 2024 and expected to:
<ul>
<li>Impact over 165 employees (approximately 33% of the company's total workforce and approximately 55% of the company's R&amp;D workforce), including changes to the leadership team</li>
<li>Implement early-stage pipeline prioritization</li>
</ul>

Sage Therapeutics Reorganizes Its Business Operations To Support Ongoing Launch Of Zurzuvae In Postpartum Depression And Focus Pipeline Development Efforts Ahead Of A Clinical Study Readout For Dalzanemdor In Huntington's Disease Expected Later This Year, Plans Workforce Reduction Of ~33%

Raymond James analyst Danielle Brill reinstates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Market Perform.

Initiation

Raymond James Reinstates Market Perform on Sage Therapeutics

B of A Securities analyst Tazeen Ahmad maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Underperform and lowers the price target from $11 to $6.

B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6

Wedbush analyst Laura Chico maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $9 to $8.

Wedbush Maintains Neutral on Sage Therapeutics, Lowers Price Target to $8

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) price target from $75 to $85. Needham analyst Laura Martin maintained a Buy rating. Reddit shares gained 0.5% to close at $70.77 on Tuesday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from $90 to $120. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Cytokinetics shares fell 2.1% to close at $54.33 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from $13 to $9. Baird analyst Joel Beatty maintained a Neutral rating. Sage Therapeutics shares fell 4.3% to close at $6.43 on Tuesday. <a href="https://www.benzinga.com/quote/SAGE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) price target from $79 to $90. Baird analyst Colin Sebastian maintained an Outperform rating. Shopify shares gained 2.1% to close at $82.58 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $590 to $650. Deutsche Bank analyst Bryan Kraft maintained a Hold rating. Netflix shares gained 2.8% to close at $721.76 on Tuesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital raised The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) price target from $360 to $460. Loop Capital analyst Laura Champine upgraded the stock from Hold to Buy. Home Depot shares gained 1.5% to close at $414.18 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from $60 to $63. Morgan Stanley analyst Meta Marshall maintained an Overweight rating. Ciena rose 2.6% to close at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $564 to $570. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 2.4% to close at $518.35 on Tuesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Blue Owl Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from $24 to $25. JMP Securities analyst Brian McKenna maintained a Market Outperform rating. Blue Owl Capital shares fell 1.8% to close at $20.35 on Tuesday. <a href="https://www.benzinga.com/quote/OWL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) price target from $38 to $44. Baird analyst David Koning maintained a Neutral rating. Genpact shares fell 1.6% to close at $38.92 on Tuesday. <a href="https://www.benzinga.com/quote/G/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think:
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/e01feb48-33dc-4d9a-8aab-90248ce8208f" alt="" style="width:557px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CIEN

CYTK

NFLX

RDDT

SHOP

SPGI

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday

Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $13 to $9.

Baird Maintains Neutral on Sage Therapeutics, Lowers Price Target to $9

Warning: SAGE is at high risk of performing badly

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $10...

Stifel Nicolaus Remains a Hold on SAGE Therapeutics (SAGE)

SAGE Therapeutics ( ($SAGE) ) just unveiled an update. Sage Therapeutics, Inc. has announced a strategic reorganization involving the departure of ...

SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit...

SAGE Therapeutics: Balancing Promising Sales Growth with Strategic Uncertainties – A Hold Rating

Morgan Stanley analyst Vikram Purohit lowered the firm's price target on Sage Therapeutics (SAGE) to $9 from $11 and keeps an Equal Weight rating o...

Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley

Small Cap

Press Releases

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE

Legal

SAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGE

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

DEADLINE ALERT for OM, SAGE, and SMCI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Comments

Sage Therapeutics

Notizie

Ultime notizie per Sage Therapeutics (NASDAQ:SAGE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO